EUVIMEDEUVIMED entdecken
Metaanalyse

Global Prevalence, Incidence, and Outcomes of Coexisting MASLD and Chronic Kidney Disease: A Meta‐Analysis

Martin T W Kueh, Jacob Kang Wen Yeo, Yiming Chen, Nicole Ying Zi Chua, Hui Lian Koh iD, Seng Pei Khaw, Hassan Jabbar, Jiong-Wei Wang iD, Kwan Lee iD, Yip Han Chin, Dan Qin Sun, Alessandro Mantovani und 4 weitere

Liver International · 2026-07 · 46 (7)

DOI: 10.1111/liv.70747 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Liver International, online erschienen am 25.06.2026. Verfasst von Martin T W Kueh und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine/Endocrinology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 137 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background & Aims Metabolic dysfunction‐associated steatotic liver disease (MASLD) is highly prevalent and increasingly recognized as a multisystem cardiometabolic disorder. The global burden, incidence and prognostic implications of coexisting chronic kidney disease (CKD) in MASLD remain uncertain.

Methods

In this meta‐analysis, we searched MEDLINE and EMBASE from inception through September 25, 2025, for observational studies reporting CKD prevalence and/or incidence among adults (≥ 18 years) with MASLD. The primary outcomes were pooled CKD prevalence, estimated using random‐effects models on the logit scale with the Hartung–Knapp adjustment, and pooled CKD incidence (per 1000 person‐years), estimated using random‐effects models with exact Poisson confidence intervals. Secondary outcomes included all‐cause mortality and cardiovascular, renal and cancer outcomes.

Results

From 2811 records, 36 observational studies met the inclusion criteria. Twenty‐three studies contributed prevalence estimates (575 615 participants; 56 248 CKD cases) and thirteen studies contributed incidence estimates (27 996 new events). The pooled global CKD prevalence among individuals with MASLD was 15.22% (95% CI 9.69–23.12). The pooled CKD incidence was 22.17 per 1000 person‐years (95% CI 11.44–32.89) in the MASLD population. Hypertension (OR 1.49, 95% CI 1.29–1.72), dyslipidaemia (OR 1.22, 95% CI 1.20–1.24) and diabetes (OR 1.94, 95% CI 1.69–2.22) were associated with higher odds of CKD in the MASLD population. All‐cause mortality rates were 18.28 per 1000 person‐years (95% CI 3.45–33.11) in coexistent MASLD and CKD, more than double those in the MASLD‐only population (7.26 per 1000 person‐years (95% CI 2.97–11.56)).

Conclusions

Coexistent CKD affects one in seven individuals with MASLD worldwide, conferring a more than two‐fold increased risk of all‐cause mortality compared with individuals with MASLD alone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal Insufficiency, ChronicNon-alcoholic Fatty Liver DiseaseHumansPrevalenceIncidenceGlobal HealthRisk FactorsComorbidity

Stichwörter der Autor:innen

MASLDchronic kidney diseaseepidemiologysteatotic liver disease

Autor:innen und Institutionen

  • Department of Internal Medicine/Endocrinology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Hospital Kuala Lumpur, Ministry of Health Malaysia, Kuala Lumpur, Malaysia.
  • Hospital Pulau Pinang, Ministry of Health Malaysia, George Town, Pulau Pinang, Malaysia.
  • Department of Surgery and Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
  • Department of Cardiovascular Medicine, Mayo Clinic Arizona, Phoenix, Arizona, USA.

ORCID-Profile: Hui Lian Koh, Jiong-Wei Wang, Kwan Lee, Giovanni Targher, Xiao-Dong Zhou, Ming-Hua Zheng

Zitieren

APA

Kueh, M. T. W., Yeo, J. K. W., Chen, Y., Chua, N. Y. Z., Koh, H. L., Khaw, S. P., Jabbar, H., Wang, J. W., Lee, K., Chin, Y. H., Sun, D. Q., Mantovani, A., Targher, G., Chew, N. W. S., Zhou, X. D., & Zheng, M. H. (2026). Global Prevalence, Incidence, and Outcomes of Coexisting MASLD and Chronic Kidney Disease: A Meta‐Analysis. Liver International, 46(7). https://doi.org/10.1111/liv.70747

Vancouver

Kueh MTW, Yeo JKW, Chen Y, Chua NYZ, Koh HL, Khaw SP, et al. Global Prevalence, Incidence, and Outcomes of Coexisting MASLD and Chronic Kidney Disease: A Meta‐Analysis. Liver International. 2026;46(7). doi:10.1111/liv.70747

BibTeX
@article{Kueh2026,
  author = {Kueh, Martin T W and Yeo, Jacob Kang Wen and Chen, Yiming and Chua, Nicole Ying Zi and Koh, Hui Lian and Khaw, Seng Pei and Jabbar, Hassan and Wang, Jiong-Wei and Lee, Kwan and Chin, Yip Han and Sun, Dan Qin and Mantovani, Alessandro and Targher, Giovanni and Chew, Nicholas W S and Zhou, Xiao-Dong and Zheng, Ming-Hua},
  title = {Global Prevalence, Incidence, and Outcomes of Coexisting MASLD and Chronic Kidney Disease: A Meta‐Analysis},
  journal = {Liver International},
  year = {2026},
  volume = {46},
  number = {7},
  doi = {10.1111/liv.70747}
}
Kostenlos starten →